Updates in the pathophysiological mechanisms of Parkinson&rsquo;s disease: Emerging role of bone marrow mesenchymal stem cells

doi:10.4252/wjsc.v8.i3.106

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9259)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

600

WORD

339

HTML

4113

Figures (1-3)

215

Tables (1-3)

199

Sum=5466

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1259

Download

2534

Sum=3793

Mar 26, 2016 (publication date) through Feb 17, 2025

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Stem Cells. Mar 26, 2016; 8(3): 106-117
Published online Mar 26, 2016. doi: 10.4252/wjsc.v8.i3.106

Table 1 Effect of treatment with bone marrow derived mesenchymal stem cells on serum transforming growth factor beta-1 and monocyte chemoattractant protein-1 levels in Parkinson’s disease model

	TGF-β1 (pg/mL)	MCP-1 (pg/mL)
Ovariectomized control	481.5 ± 7.5	88.1 ± 0.9
PD untreated	691.2 ± 8.0^a	112.1 ± 1.9^a
PD + BM-MSCs	489.7 ± 13.0^c	89.6 ± 2.0^c

Data are represented as mean ± SE of 8 rats/group.

^aSignificant change at P < 0.05 in comparison with the ovariectomized control group;

^cSignificant change at P < 0.05 in comparison with the untreated PD group. PD: Parkinson’s disease; BM-MSCs: Bone marrow derived mesenchymal stem cells; TGF-β1: Transforming growth factor beta-1; MCP-1: Monocyte chemoattractant protein-1.

Citation: Ahmed HH, Salem AM, Atta HM, Eskandar EF, Farrag ARH, Ghazy MA, Salem NA, Aglan HA. Updates in the pathophysiological mechanisms of Parkinson’s disease: Emerging role of bone marrow mesenchymal stem cells. World J Stem Cells 2016; 8(3): 106-117
URL: https://www.wjgnet.com/1948-0210/full/v8/i3/106.htm
DOI: https://dx.doi.org/10.4252/wjsc.v8.i3.106